Acura Pharmaceuticals (STU:HD4B) Research & Development: €1.30 Mil (TTM As of Dec. 2021)


STU:HD4B Acura Pharmaceuticals Inc STU:HD4B
16 GF Score
Price €0.20
View Full Analysis

What is Acura Pharmaceuticals Research & Development?

Acura Pharmaceuticals STU:HD4B 16 Research & Development is €1.30 Mil as of Dec. 2021. GuruFocus rates STU:HD4B with a GF Score™ of 16/100.

Research & Development is the aggregate amount of research and development expenses during the year. Acura Pharmaceuticals's Research & Development for the three months ended in Dec. 2021 was €0.30 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2021 was €1.30 Mil.

Acura Pharmaceuticals  (STU:HD4B) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Acura Pharmaceuticals Research & Development Related Terms

Acura Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Acura Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acura Pharmaceuticals Research & Development Chart

Acura Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.14 1.55 1.36 1.46 1.35

Acura Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.34 0.32 0.33 0.30
STU:HD4B
16GF Score
Acura Pharmaceuticals Inc STU:HD4B
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acura Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €1.30 Mil mean?
Acura Pharmaceuticals (STU:HD4B) has a Research & Development of €1.30 Mil as of Dec. 2021. Research and development expense is the total cost for research and development activities. View historical data on Acura Pharmaceuticals and its competitors.
Is Acura Pharmaceuticals' Research & Development too high?
Acura Pharmaceuticals' current Research & Development is €1.30 Mil. Overall, Acura Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Acura Pharmaceuticals' Research & Development compare to VFRM and THCT?
Acura Pharmaceuticals' Research & Development of €1.30 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Acura Pharmaceuticals and its competitors. Acura Pharmaceuticals's current Research & Development is €1.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acura Pharmaceuticals stock overvalued right now?
Acura Pharmaceuticals (STU:HD4B) has a current Research & Development of €1.30 Mil. The current Research & Development is €1.30 Mil. Acura Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Acura Pharmaceuticals (STU:HD4B), the current Research & Development is €1.30 Mil as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acura Pharmaceuticals Business Description

Address 616 N. North Court, Suite 120, Palatine, IL, USA, 60067
Acura Pharmaceuticals Inc is a drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. It has discovered and developed three proprietary platform technologies which can be used to develop multiple products. Its Limitx Technology is being developed to minimize the risk of overdose, its Aversion Technology is intended to address methods of abuse associated with opioid analgesics while its Impede Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine. It operates in single segment being the research, development and commercialization of technologies and products intended to address safe use of medications.
16GF Score

Get the complete analysis for STU:HD4B

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price